Reason for request
Re-assessment of the IAB
-
Clinical Benefit
| Substantial |
the actual benefit of BEROMUN is substantial in the indication "treatment of soft tissue sarcoma of the limbs : - for subsequent removal of the tumour so as to prevent or delay amputation ; - in the palliative situation, for irresectable soft tissue sarcoma. " |
Clinical Added Value
| minor |
In view of the available data, the Committee considers that the BEROMUN/melphalan combination provides : - a minor IAB (level IV) in the treatment of soft tissue sarcoma of the limbs for subsequent removal of the tumour, so as to prevent or delay amputation, - a minor IAB (level IV) in irresectable soft tissue sarcoma. |
